AB1617-HPR ASSESSING THE IMPACT OF A MULTIDISCIPLINARY CARE MODEL ON AN ESTABLISHED COHORT OF RHEUMATOID ARTHRITIS PATIENTS IN COLOMBIA – A TEN-YEAR REAL-LIFE COHORT EXPERIENCE
Authors: P. Santos-Moreno, L. Villarreal, G. S. Rodríguez-Vargas, F. Rodriguez-Florido, P. Rodríguez-Linares, N. Gutiérrez, A. Rojas-Villarraga, I. Ramirez, E. Cardozo, M. F. Linares-Contreras, A. Mayor-González, M. F. Cubides Acosta, M. J. Mantilla
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Rheumatoid arthritis (RA) is a chronic, autoimmune disease that requires a targeted therapy focused on a multidisciplinary approach in which several specialties intervene to improve the illness outcome. <h3>Objectives:</h3> The aim of the present study is to describe and analyze the impact of the multidisciplinary care model (Rheumatologist, rehabilitation and physical medicine, nutritionist, psychology and medical doctor) on disease activity in a long-standing RA cohort. <h3>Methods:</h3> A retrospective observational study was started involving adult RA patients under multidisciplinary care model. Data were recorded since January 2011 to June 2021 from databases. The analysis focused on patients' disease activity, assessed through measures such as DAS28 and RAPID3, as well as functional capacity, evaluated using MDHAQ. To describe numerical variables, normality Kolmogorov-Smirnov test, was conducted. Numerical data are presented as median and interquartile range (IQR), and comparisons were made using the Mann-Whitney U test. Categorical variables are described as percentages and underwent analysis through the chi-square test. <h3>Results:</h3> 3163 prevalent patients were included. 72.8% (2302) were under conventional therapy and 27.2% (861) in biologic therapy. 81% (2564) were women. There were more men on biologic therapy than conventional therapy (p=0.015; 21.7% vs. 17.9%). The median age of total group was 67 years (14) being higher in conventional therapy group (p &lt;0.05). Seropositive for rheumatoid factor (RF) was 77.6% (2228), and 73.4% (1934) for anti-CCP without differences between groups. 39.1% (1019) of patients were erosive being higher in the biologics group (p=0.001; 44.7% vs 37.2%). Current MDHAQ in whole group was 0.40 (0.48), and was slightly higher in the biological 0.04 (0.57) vs conventional 0.04 (0.46) group p &lt;0.046. RAPID3 in the whole group was 6 (4) without differences between groups of treatment. DAS28 at program entry for all group was 3.41 (1.9) and the latest DAS28 2.1 (0.49) (Figure 1). There was statistically significant difference p&lt;0.05 between initial DAS28 at model entry and at end in the whole group. As well as the initial DAS28 vs. the final DAS28 in the conventional group (p&lt;0.05; 3.32 IQR 1.79 vs 2.1 IQR 0.49) and in biologic therapy (p&lt;0.05; 3.91 IQR 2.3 vs 2.1 IQR 0.57) (Figure 1). <h3>Conclusion:</h3> The introduction of a multidisciplinary care model for RA has yielded promising outcomes in decreasing disease activity among patients, and improving quality of life of RA patients. However, a more intricate comprehension of the diverse variables influencing the disease is crucial. This emphasizes the need for further studies to deepen our understanding, refine insights, and improve the effectiveness of holistic management strategies. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> Pedro Santos-Moreno Abbvie, Abbott, Biopas-UCB, Bristol, Janssen, Pfizer, Roche, Sanofi, Abbvie, Abbott, Biopas-UCB, Bristol, Janssen, Pfizer, Roche, Sanofi, Laura Villarreal: None declared, Gabriel-Santiago Rodríguez-Vargas: None declared, Fernando Rodriguez-Florido: None declared, Pedro Rodríguez-Linares: None declared, Nicolás Gutiérrez: None declared, Adriana Rojas-Villarraga: None declared, Ivania Ramirez: None declared, Eva Cardozo: None declared, María-Fernanda Linares-Contreras: None declared, Andrys Mayor-González: None declared, Maria Fernanda Cubides Acosta: None declared, Marta Juliana Mantilla: None declared.